Thursday, 24 May 2012

Nystop



nystatin

Dosage Form: powder
Nystop®

Nystatin Topical

Powder USP

For topical use only.

Not for ophthalmic use.



Nystop Description


Nystatin is a polyene antifungal antibiotic obtained from Streptomyces nursei. The molecular formula for Nystatin is C47H75NO17. The molecular weight of Nystatin is 926.1. Structural formula:



Nystatin Topical Powder USP is for dermatologic use.


Nystatin Topical Powder USP contains 100,000 USP nystatin units per gram dispersed in talc.



Nystop - Clinical Pharmacology



Pharmacokinetics


Nystatin is not absorbed from intact skin or mucous membrane.



Microbiology


Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes.


Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C, tropicalis, C. guillier mondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.



Indications and Usage for Nystop


Nystatin Topical Powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species.


This preparation is not indicated for systemic, oral, intravaginal or ophthalmic use.



Contraindications


Nystatin Topical Powder is contraindicated in patients with a history of hypersensitivity to any of its components.



Precautions



General


Nystatin Topical Powder should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.


If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.



INFORMATION FOR THE PATIENT


Patients using this medication should receive the following information and instructions:


  1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.

  2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.

  3. If symptoms of irritation develop, the patient should be advised to notify the physician promptly.


Laboratory Tests


If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.



Carcinogenesis, Mutagenesis, Impairment of Fertility


No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility.



Pregnancy:


Teratogenic Effects

Category C. Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical preparations should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.



Nursing Mothers


It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.



Pediatric Use


Safety and effectiveness have been established in the pediatric population from birth to 16 years. (See DOSAGE AND ADMINISTRATION).



Adverse Reactions


The frequency of adverse events reported in patients using nystatin topical preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS: General.)



Nystop Dosage and Administration


Very moist lesions are best treated with the topical dusting powder.



Adults and Pediatric Patients (Neonates and Older):


Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.



How is Nystop Supplied


Nystop® Nystatin Topical Powder USP is supplied as 100,000 units nystatin per gram in 15 g, 30 g and 60 g plastic squeeze bottles.


(NDC 0574-2008-15)

(NDC 0574-2008-30)

(NDC 0574-2008-02)



STORAGE


Store at controlled room temperature 15°-30°C (59°-86°F); avoid excessive heat (40°C;104°F).



Paddock Laboratories, Inc.

Minneapolis, MN 55427

(10-07)



PRINCIPAL DISPLAY PANEL- 15 grams label


Nystop®

Nystatin Topical Powder, USP


NDC 0574-2008-15


100,000 USP UNITS PER GRAM


Rx ONLY


USUAL DOSAGE: Apply to affected

area 2 or 3 times daily.


STORAGE: Store at controlled room

temperature 15°-30°C (59°-86°F);

avoid excessive heat (40°C; 104°F).


NET WEIGHT 15 GRAMS


Paddock

Laboratories, Inc.










Nystop 
nystatin  powder










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0574-2008
Route of AdministrationTOPICALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Nystatin (Nystatin)Nystatin100000 [USP'U]  in 1 g






Inactive Ingredients
Ingredient NameStrength
Talc 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      


















Packaging
#NDCPackage DescriptionMultilevel Packaging
10574-2008-1515 g In 1 BOTTLE, PLASTICNone
20574-2008-3030 g In 1 BOTTLE, PLASTICNone
30574-2008-0260 g In 1 BOTTLE, PLASTICNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA06411808/16/1996


Labeler - Paddock Laboratories, Inc. (086116803)









Establishment
NameAddressID/FEIOperations
Paddock Laboratories, Inc.086116803MANUFACTURE
Revised: 08/2010Paddock Laboratories, Inc.

More Nystop resources


  • Nystop Side Effects (in more detail)
  • Nystop Use in Pregnancy & Breastfeeding
  • Nystop Support Group
  • 1 Review for Nystop - Add your own review/rating


  • Nystop Topical Advanced Consumer (Micromedex) - Includes Dosage Information

  • Nystop Powder MedFacts Consumer Leaflet (Wolters Kluwer)

  • Nystop Concise Consumer Information (Cerner Multum)

  • Pediaderm AF Cream MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Nystop with other medications


  • Cutaneous Candidiasis
  • Vaginal Yeast Infection

No comments:

Post a Comment